Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Enos Bernasconi and Manuel Battegay.
Enos Bernasconi
Connection Strength
0.882
Manuel Battegay
  1. Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. Open Forum Infect Dis. 2016 Jan; 3(1):ofw022.
    View in: PubMed
    Score: 0.164
  2. HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. J Acquir Immune Defic Syndr. 2019 08 15; 81(5):508-515.
    View in: PubMed
    Score: 0.052
  3. Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. Clin Infect Dis. 2019 02 15; 68(5):827-833.
    View in: PubMed
    Score: 0.051
  4. Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evol. 2018 07; 4(2):vey024.
    View in: PubMed
    Score: 0.049
  5. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature. 2018 09; 561(7723):406-410.
    View in: PubMed
    Score: 0.049
  6. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematol Oncol. 2018 Dec; 36(5):757-764.
    View in: PubMed
    Score: 0.049
  7. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. J Exp Med. 2018 06 04; 215(6):1589-1608.
    View in: PubMed
    Score: 0.048
  8. Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study. Kidney Int Rep. 2018 Sep; 3(5):1089-1099.
    View in: PubMed
    Score: 0.048
  9. Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Mol Biol Evol. 2018 01 01; 35(1):27-37.
    View in: PubMed
    Score: 0.047
  10. Adverse events of raltegravir and dolutegravir. AIDS. 2017 08 24; 31(13):1853-1858.
    View in: PubMed
    Score: 0.046
  11. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infect Dis. 2017 07 06; 17(1):476.
    View in: PubMed
    Score: 0.045
  12. Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clin Infect Dis. 2017 05 01; 64(9):1275-1278.
    View in: PubMed
    Score: 0.045
  13. Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. Medicine (Baltimore). 2017 Jan; 96(2):e5849.
    View in: PubMed
    Score: 0.044
  14. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol. 2015 Jul 08; 15:79.
    View in: PubMed
    Score: 0.039
  15. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology. 2011 May; 53(5):1446-54.
    View in: PubMed
    Score: 0.029
  16. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010 Apr; 138(4):1338-45, 1345.e1-7.
    View in: PubMed
    Score: 0.027
  17. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010; 15(3):413-23.
    View in: PubMed
    Score: 0.027
  18. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis. 2008 Apr 15; 46(8):1299-309.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.